SLIDE 1
ALLOGENEIC HCT IN PTCL
- WHO
- WHEN
- HOW
T RANSPLANTATION FOR PTCL: A MERICAN P ERSPECTIVE Andrei Shustov, - - PowerPoint PPT Presentation
T RANSPLANTATION FOR PTCL: A MERICAN P ERSPECTIVE Andrei Shustov, - - PowerPoint PPT Presentation
A LLOGENEIC H EMATOPOIETIC C ELL T RANSPLANTATION FOR PTCL: A MERICAN P ERSPECTIVE Andrei Shustov, M.D. University of Washington Seattle WA A LLOGENEIC HCT IN PTCL WHO WHEN HOW A RE A LL A LLOGRAFTS THE S AME ? Myeloablative
SLIDE 2
SLIDE 3
ARE ALL ALLOGRAFTS THE SAME?
- Myeloablative conditioning
- Reduced-intensity conditioning
- Non-Myeloablative conditioning
- Cord blood transplants
SLIDE 4
Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis Neha Mehta-Shah, MD1, Stephanie Teja1, Yu Tao, MD2, Amanda F. Cashen, MD1, Anne Beaven, MD3, Matthew A. Lunning, DO4, Onder Alpdogan, MD5, Pierluigi Porcu, MD5, Mackenzie Wiggin6, Kevin W Song, MD7, Musa Alzahrani, MBBS7,8, Parastoo B. Dahi, MD9, Alison J. Moskowitz, MD9, Steven M. Horwitz, MD9 and Eric D. Jacobsen, MD6
1Washington University in St. Louis, St. Louis, MO; 2Siteman Biostatistics Shared Resource, Washington
University in St. Louis, St. Louis, MO; 3University of North Carolina, Chapel Hill, NC; 4Univerisity of Nebraska, Omaha, NE; 5Thomas Jefferson University, Philadelphia, PA; 6Dana Farber Cancer Institute, Boston, MA;
7British Columbia Cancer Agency, Vancouver, Canada; 8King Saud University, Riyadh, Saudi Arabia; 9Memorial Sloan Kettering Cancer Center, New York, NY
SLIDE 5
ALLO-HCT IN PTCL: PATIENT CHARACTERISTICS
Courtesy of N. Mehta-Shah and S. Horwitz; ASH-2017
SLIDE 6
ALLO-HCT IN PTCL: SURVIVAL OUTCOMES
OS and PFS (N=301) PFS by Dz Status prior to HCT Time (months) Time (months)
Courtesy of N. Mehta-Shah and S. Horwitz; ASH-2017
SLIDE 7
ALLO-HCT IN PTCL: HISTOLOGY SPECIFIC SURVIVAL
Courtesy of N. Mehta-Shah and S. Horwitz; ASH-2017
SLIDE 8
ALLO-HCT IN PTCL VS CTCL
OS: PTCL vs CTCL PFS: PTCL vs CTCL
Courtesy of N. Mehta-Shah and S. Horwitz; ASH-2017
SLIDE 9
ALLO-HCT IN PTCL: TRM AND GVHD
TRM by donor type
Courtesy of N. Mehta-Shah and S. Horwitz; ASH-2017
SLIDE 10
FHCRC EXPERIENCE
SLIDE 11
FHCRC EXPERIENCE
65% 66%
15%
3-year
SLIDE 12
PTCL: WHO SHOULD GET ALLOTRANSPLANT
- Patients with relapsed and refractory PTCL
- Patients with post-autoHCT relapse of PTCL
- Newly diagnosed PTCL:
- high-risk disease (IPI* = 4-5)
- High-risk histology
- Hepatosplenic T-cell lymphoma
- G-d T-cell lymphomas
- Adult T-cell Leukemia/Lymphoma*
SLIDE 13